Discover Roche’s Scientific Program and Explore Cutting-Edge Insights!
Hear from leading experts as they discuss the latest faricimab data, translate evidence into clinical practice, and explore real-world insights through an exciting game-show format.
Attend high-impact Scientific Presentations and browse breakthrough Posters that highlight the latest clinical and scientific advances.
Date |
Time |
Indication |
Topic |
Presenter |
Venue |
13 Dec |
09:36-09:42 |
DME |
Update on Faricimab for Diabetic Macular Edema: New Clinical Features of Eyes in the RHONE-X Long-Term Extension Study |
Young Hee Yoon |
Meeting Room 7-9 |
13 Dec |
10:18-10:24 |
nAMD |
Greater Anatomical Improvements With Faricimab vs Aflibercept 8 Weeks After Injections: A TENAYA/LUCERNE Post-Hoc Analysis |
Tai-Chi Lin |
Meeting Room 7-9 |
13 Dec |
10:00-10:06 |
nAMD |
Four-Year Outcomes of Faricimab in Neovascular Age-Related Macular Degeneration: Safety and Efficacy Results From the AVONELLE-X Long-Term Extension Trial |
Timothy Lai |
Meeting Room 7-9 |
13 Dec |
15:48-15:54 |
RWD |
Real-World Outcomes of Faricimab in Patients with nAMD (Neovascular Age-Related Macular Degeneration) and DME (Diabetic Macular Edema) from a Global, Prospective Observational Study: The VOYAGER Study |
Voraporn Chaikitmongkol |
Meeting Room 7-9 |
14 Dec |
09:00-09:06 |
RVO |
Association of Early Macular Leakage Resolution with Extended Dosing Intervals in Patients With Retinal Vein Occlusion: A Post Hoc Analysis of the BALATON/COMINO Trials |
Hemal Mehta |
Meeting Room 7-9 |
14 Dec |
09:30-09:36 |
PCV |
Faricimab for Polypoidal Choroidal Vasculopathy: One-Year Results from the Phase 3b/4 SALWEEN Trial |
Gemmy Cheung |
Meeting Room 7-9 |
14 Dec |
11:12-11:18 |
Preclinical |
Potential Therapeutic Effect of Angiopoetin-2/Vascular Endothelial Growth Factor-2 Inhibition on Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION): A Rat Anterior Ischemic Optic Neuropathy (rAION) Model Pilot Study |
Pei-Kang Liu |
Meeting Room 7-9 |
14 Dec |
12:00-12:06 |
nAMD |
Baseline and Early Treatment Response Variables of Faricimab Durability in Treatment-Naïve neovascular age-related macular degeneration |
Marie Joan Loy |
Meeting Room 7-9 |
14 Dec |
12:18-12:24 |
RWD |
Effectiveness and Safety of Faricimab in Eyes With nAMD (Neovascular Age-Related Macular Degeneration) and DME (Diabetic Macular Edema) Beyond Year 1: Results From the UK FARWIDE-nAMD and FARWIDE-DME Study |
Kenneth Fong |
Meeting Room 7-9 |
Date |
Time |
Indication |
Topic |
Presenter |
Venue |
e-Poster |
DME |
Comparative Efficacy of Faricimab for the Treatment of Diabetic Macular Edema at 1 and 2 Years: A Systematic Literature Review and Network Meta-Analysis |
Colin Tan |
NA |
|
Poster |
DME |
Automated Quantification of Retinal Fluid in Patients with Diabetic Macular Edema: Analysis of Faricimab vs Aflibercept in YOSEMITE and RHINE |
Simon Szeto |
NA |
|
e-Poster |
nAMD/DME |
Indirect comparison of the relative effectiveness of faricimab vs aflibercept 8 mg in diabetic macular edema and neovascular age-related macular degeneration |
Adrian Koh |
NA |
Date |
Time |
Indication |
Topic |
Presenter |
Venue |
13 Dec |
10:18-10:24 |
nAMD |
Long-Term Efficacy and Safety of the Port Delivery Platform With Ranibizumab in Patients With nAMD: Results From the Ladder- and Archway-to-Portal Trials |
Yew Sen Yuen |
NA |
e-Poster |
nAMD |
Assessing a 36-Week Refill-Exchange Regimen for the Port Delivery Platform With Ranibizumab in Patients With up to 2 Years’ Diagnosis of Neovascular Age-Related Macular Degeneration: Phase 3b Sightspire Trial |
Thanapong Somkijrungroj |
NA |
|
e-Poster |
DME/DR |
Impact of Continuous Versus As-Needed Treatment in Bilateral Diabetic Macular Edema (DME): Efficacy and Safety Outcomes in Port Delivery Platform−Treated Study Eyes Versus Intravitreal Injection−Treated Fellow Eyes in the Pagoda Trial |
Yi-Ting Hsieh |
NA |
Date |
Time |
Indication |
Topic |
Presenter |
Venue |
14 Dec |
14:00-14:06 |
UME |
Intraocular Inflammation, Uveitis & Scleritis Evaluation of the Role of Interleukin-6 and Vascular Endothelial Growth Factor in Uveitic Macular Edema and Uveitis |
Yew Sen Yuen |
Meeting Room 4-6 |
14 Dec |
15:00-15:06 |
UME |
Interleukin-6 inhibition with vamikibart in patients with uveitic macular edema: Data from phase 3 MEERKAT and SANDCAT trials |
Yew Sen Yuen |
Meeting Room 4-6 |
Date |
Time |
Indication |
Topic |
Presenter |
Venue |
14 Dec |
09:12-09:18 |
Retina |
The Asia Pacific (APAC) Vision Health Survey Report: An Urgent Challenge and a Critical Conjunction |
Andrew Chang |
Meeting Room 4-6 |
12th December | 13:00-14:00 GMT+8 (Manila Time)
Function 3
13th December | 13:00-14:00 GMT+8 (Manila Time)
Function 3
A/Prof. Adrian Koh is joined by leading expert Prof. Gemmy Cheung to dissect the critical 1-year results from the SALWEEN study. This podcast is a deep dive into the 1-year SALWEEN data readout, focusing on the implications for patients with PCV. The experts analyze the key clinical takeaways from the SALWEEN data, discussing its impact on clinical treatment paradigms for PCV patients.
SALWEEN 1-Year Insights: Redefining PCV Care
This meeting is intended for healthcare professionals outside the UK and USA.